company background image

BioqualOTCPK:BIOQ Stock Report

Market Cap







23 Oct, 2021


Company Financials
BIOQ fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance4/6
Financial Health6/6

BIOQ Overview

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Bioqual
Historical stock prices
Current Share PriceUS$86.50
52 Week HighUS$62.00
52 Week LowUS$92.00
1 Month Change2.37%
3 Month Change23.57%
1 Year Change22.24%
3 Year Change147.14%
5 Year Change167.22%
Change since IPO28,732.18%

Recent News & Updates

Shareholder Returns

BIOQUS Life SciencesUS Market

Return vs Industry: BIOQ underperformed the US Life Sciences industry which returned 35.7% over the past year.

Return vs Market: BIOQ underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is BIOQ's price volatile compared to industry and market?
BIOQ volatility
BIOQ Beta-0.40
Industry Beta0.97
Market Beta1

Stable Share Price: Insufficient data to determine BIOQ's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine BIOQ's volatility change over the past year.

About the Company

1981n/aMark Lewis

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays.

Bioqual Fundamentals Summary

How do Bioqual's earnings and revenue compare to its market cap?
BIOQ fundamental statistics
Market CapUS$77.37m
Earnings (TTM)US$5.94m
Revenue (TTM)US$58.24m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIOQ income statement (TTM)
Cost of RevenueUS$39.82m
Gross ProfitUS$18.42m

Last Reported Earnings

Aug 31, 2021

Next Earnings Date


Earnings per share (EPS)6.64
Gross Margin31.62%
Net Profit Margin10.20%
Debt/Equity Ratio0%

How did BIOQ perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is Bioqual undervalued compared to its fair value and its price relative to the market?


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: BIOQ ($86.5) is trading above our estimate of fair value ($29.29)

Significantly Below Fair Value: BIOQ is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: BIOQ is good value based on its PE Ratio (13x) compared to the US Life Sciences industry average (48x).

PE vs Market: BIOQ is good value based on its PE Ratio (13x) compared to the US market (18.2x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIOQ's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: BIOQ is good value based on its PB Ratio (2.3x) compared to the US Life Sciences industry average (6.1x).

Future Growth

How is Bioqual forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioqual has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Bioqual performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BIOQ has high quality earnings.

Growing Profit Margin: BIOQ's current net profit margins (10.2%) are higher than last year (9.1%).

Past Earnings Growth Analysis

Earnings Trend: BIOQ's earnings have grown by 9.5% per year over the past 5 years.

Accelerating Growth: BIOQ's earnings growth over the past year (27.1%) exceeds its 5-year average (9.5% per year).

Earnings vs Industry: BIOQ earnings growth over the past year (27.1%) underperformed the Life Sciences industry 56.9%.

Return on Equity

High ROE: BIOQ's Return on Equity (17.7%) is considered low.

Financial Health

How is Bioqual's financial position?

Financial Position Analysis

Short Term Liabilities: BIOQ's short term assets ($29.3M) exceed its short term liabilities ($8.5M).

Long Term Liabilities: BIOQ's short term assets ($29.3M) exceed its long term liabilities ($11.4M).

Debt to Equity History and Analysis

Debt Level: BIOQ is debt free.

Reducing Debt: BIOQ has no debt compared to 5 years ago when its debt to equity ratio was 5.7%.

Debt Coverage: BIOQ has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BIOQ has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet


What is Bioqual current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: BIOQ's dividend (1.45%) is higher than the bottom 25% of dividend payers in the US market (1.29%).

High Dividend: BIOQ's dividend (1.45%) is low compared to the top 25% of dividend payers in the US market (3.47%).

Stability and Growth of Payments

Stable Dividend: BIOQ's dividends per share have been stable in the past 10 years.

Growing Dividend: BIOQ's dividend payments have increased over the past 10 years.

Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (18.8%), BIOQ's dividend payments are well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Mark Lewis (66 yo)



Dr. Mark G. Lewis, PhD has been the Chief Executive Officer and President of BIOQUAL, Inc. since June 3, 2013 and November 15, 2010 respectively. Dr. Lewis served as Director of Research at BIOQUAL Inc. F...

Board Members

Experienced Board: BIOQ's board of directors are seasoned and experienced ( 29.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Bioqual, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Bioqual, Inc.
  • Ticker: BIOQ
  • Exchange: OTCPK
  • Founded: 1981
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$77.367m
  • Shares outstanding: 894.42k
  • Website:


  • Bioqual, Inc.
  • 9600 Medical Center Drive
  • Suite 101
  • Rockville
  • Maryland
  • 20850-3336
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/23 22:09
End of Day Share Price2021/10/22 00:00
Annual Earnings2021/05/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.